Internal tandem duplication (ITD) mutations in the Fms-related tyrosine kinase 3 (FLT3) gene (FLT3-ITD) are associated with poor prognosis in patients with acute myeloid leukemia (AML). Due to the development of drug resistance, few FLT3-ITD inhibitors are effective against FLT3-ITD + AML. In this study, we show that FLT3-ITD activates a novel pathway involving p21 Cdkn1a (p21) and pre-B cell leukemia transcription factor 1 (Pbx1) that attenuates FLT3-ITD cell proliferation and is involved in the development of drug resistance. FLT3-ITD up-regulated p21 expression in both mouse bone marrow c-kit cells delayed the emergence of cells that were refractory to AC220, whereas p21 silencing accelerated their development. These data indicate that FLT3-ITD is capable of inhibiting FLT3-ITD + cell proliferation through the p21/Pbx1 axis and that treatments that antagonize FLT3-ITD contribute to the subsequent development of cells that are refractory to a FLT3-ITD inhibitor by disrupting p21 expression.
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Introduction
The cyclin-dependent kinase inhibitor p21 Cdkn1a (p21) was originally identified as a mediator of p53-induced growth arrest [1, 2] and regulates the proliferation of diverse cell types by modulating cell cycle, apoptosis and differentiation [3] [4] [5] . However, cells in which p53 is not activated still utilize p21-dependent cell cycle control [6] [7] [8] . P21 is highly expressed in hematopoietic stem cells (HSCs) and maintains quiescence [8] . The loss of p21 in HSCs increases cell cycle progression but has only a marginal effect on marrow cellularity or peripheral blood cell counts [8] . In contrast, p21 can facilitate the proliferation of normal hematopoietic progenitor cells (HPCs) ex vivo following stimulation with hematopoietic growth factors [9] [10] [11] [12] . These findings suggest that p21 has a differentiation stage-specific function in the hematopoietic system. In addition to regulating the cell cycle [1, 2, 6, 7, 13] , p21 can modulate the activity of a number of transcription factors and co-activators, such as Stat3 [13, 14] , estrogen receptorα [15] , (Ccaat-enhancer-binding protein α (C/EBPα) [16, 17] and c-Myc [18] , suggesting that it may regulate cell fate by influencing gene expression [19] . Internal tandem duplication (ITD) mutations in the Fms-related tyrosine kinase 3 (FLT3) gene (FLT3-ITD) are found in 20-30% of patients with acute myeloid leukemia (AML) and are associated with a poor prognosis [20, 21] . Few FLT3-ITD inhibitors are effective against FLT3-ITD + AML due to the emergence of drug-resistant cells [22, 23] . For instance, AC220
(Quizartinib), a second-generation class III tyrosine kinase inhibitor (TKI), which has been used to treat FLT3-ITD + AML in clinical trials, is a more potent and specific FLT3-ITD inhibitor than other TKIs [22, 24] ; however, prolonged exposure to AC220 could generate FLT3-ITD + cells that are resistant to AC220 [25] . The mechanisms responsible for drug resistance include the acquisition of mutations in the FLT3 gene, the activation of other pro-survival pathways and microenvironment-mediated resistance [22, 23] ; however, additional mechanisms responsible for the drug resistance of FLT3-ITD + AML cells remain to be investigated. Previous studies have
shown that FLT3-ITD enhances p21 expression through Stat5 [26] , whereas the FLT3-ITD inhibitor SU5614 decreases p21 expression in Ba/F3 cells expressing FLT3-ITD [27] . P21 downregulation by the FLT3-ITD inhibitor suggests that treatments that antagonize FLT3-ITD may destroy p21 function and aberrantly affect FLT3-ITD + cell proliferation. However, the functional role of p21 in FLT3-ITD signaling and FLT3-ITD-induced drug resistance remains unknown.
In the present study, we identified a p21 signaling pathway downstream of FLT3-ITD that negatively affects proliferation and is associated with drug resistance in FLT3-ITD + cells. An analysis of the genes that are modulated by p21 deletion in FLT3-ITD-transformed HPCs revealed that p21 modulates the expression of pre-B cell leukemia transcription factor 1 (Pbx1), a proto-oncogene that critically regulates HSC and HPC function [28, 29] . Silencing Pbx1 and p21 expression in FLT3-ITD-transformed HPCs revealed that the interaction between FLT3-ITD-activated p21 and Pbx1 negatively regulated FLT3-ITD + HPC proliferation. In addition, the down-regulation of p21 resulting from FLT3-ITD inhibition by AC220 accelerated the emergence of FLT3-ITD + cells that were resistant to AC220. This study is the first report to show how treatments targeting FLT3-ITD can lead to drug resistance.
Materials and Methods Animals
Medicine (Permit Numbers IZ21-24, IZ21-25, and IZ21-26 ) and the Indiana University School of Medicine (Study Number 2939) approved all of the experimental procedures.
Antibodies and cytokines
Anti-FcγIII/II receptor antibody, allophycocyanin (APC)-conjugated anti-mouse c-kit antibody (clone 2B8), phycoerythrin (PE)-conjugated Annexin V and PE-Cy7-conjugated antiSca-1 antibody (E13-161.7), along with streptavidin-APC-Cy7, rat IgG2a, rat IgG2b, 7-actinomycin-D (7-AAD) and anti-p27 monoclonal antibodies were all purchased from BD Biosciences (San Diego, CA). Biotinylated antibodies against lineage markers, including CD5, B220, CD11b, Gr-1, 7-4 and Ter119, were purchased from Miltenyi Biotec (Auburn, CA). The antiphospho-FLT3 antibody (Tyr591 33G6) and PE-conjugated anti-rabbit IgG (Fab') were obtained from Cell Signaling (Danvers, MA). Hoechst 33342 was purchased from Molecular Probes (Eugene, OR). Recombinant murine (rm) interleukin-3 (IL-3), recombinant human (rh) Fms-related tyrosine kinase 3 (FLT3) ligand (FL) and rh-thrombopoietin (TPO) were obtained from R&D Systems (Minneapolis, MN). Rm-stem cell factor (SCF) was purchased from BioVision Research Products (Mountain View, CA). Pyronin Y, AG1296, PD98059 and LY294002 were obtained from Wako Pure Chemical Industries (Osaka, Japan). AC220 (Quizartinib) was obtained from Selleckchem.com (Houston, TX). An Akt inhibitor, etoposide, and pifithrin-α were purchased from Calbiochem (Gibbstown, NJ). H89 was purchased from Upstate Biotechnology (Lake Placid, NY). The anti-actin (I-19) and anti-p21 (F-5) antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
Cell culture, plasmid transfection, retroviral transduction and shRNA knockdown
Ba/F3 cells expressing wild-type human FLT3 or FLT3-ITD have been described previously [30] [31] [32] . Retroviral transduction of human wild-type FLT3 and N51-FLT3-ITD in an MSCV-IRES-EGFP vector into mouse bone marrow cells was performed as previously described [9, 30] . After sequential infections, the GFP + cells were sorted using a FACSAria II flow cytometer (BD Biosciences), and 25,000 GFP + cells were cultured in semisolid methylcellulose or 0.3% agar with 30% heat-inactivated fetal bovine serum (HI-FBS) without hematopoietic growth factors. Colony formation was scored after 7 or 14 days. In replicate liquid cultures, cells were stained for c-kit, Sca-1 and standard lineage markers at the time of plating or after incubation in liquid culture. For shRNA-mediated knockdown of Pbx1, bone marrow cells from the p21 +/+ and p21 -/-mice were transduced with a control shRNA or Pbx1 shRNA (shRNA-1 or shRNA-2) using a pSINsi-mU6 plasmid (TAKARA Biotechnology, Otsu, Japan). The sequences of Pbx1 shRNA-1 and shRNA-2 were 5'-CGA TCA ATG CAT ATT TGC A-3' and 5'-GGA GCA TTC CGA CTA CAG A-3', respectively. To transduce shRNAs targeted against p21 and/or Pbx1 into the Flt3-ITD + Ba/F3 cells, non-transfected Ba/F3 cells were transduced with MSCV-FLT3-ITD (N51)-EGFP using a retrovirus. The GFP-positive cells were sorted and electroporated with a p21-specific shRNA that had been cloned into the pBAsimU6 Pur DNA vector (TAKARA Biotechnology). The sequence of the p21 shRNA was 5'-GCA GAT TGG TCT GCA A-3'. Stable transformants were selected with 3 μg/ml puromycin and frozen for storage. The cells were subsequently transfected with a pSINsi-mU6 plasmid containing a Pbx1 shRNA, and G418-resistant cells were selected and used for the analyses.
cDNA microarrays and quantitative RT-PCR . The PCR primers were: Pbx1, 5'-AAGCCGGACCAGG CCCATCT-3' and 5'-GGCCTCGCACGTGCTCTGTT-3'; Evi-1, 5'-GCAGCGACATGTGCG CAACA-3' and 5'-GAGGCGAGGACGTTGCCGTC-3'; p21, 5'-GTACTTCCTCTGCCCTGC-3' and 5'-AGAGTGCAAGACAGCGACAA-3'; and Hprt, 5'-TGGACAGGACTGAAAGACTT GCTCG-3' and 5'-GGCCACAATGTGATGGCCTCCC-3'. The PCR cycling parameters were 95°C for 10 min, followed by 50 cycles at 95°C for 15 s and 60°C for 1 min. The differences in the mRNA levels were calculated using the ΔCT method and were normalized to Hprt.
Statistical analysis
The data are expressed as the means ± standard errors of the mean (SEM). Significant differences were determined using a two-tailed Student's t-test in Microsoft Excel™ (Microsoft Corp., Seattle, WA).
Results

FLT3 signaling up-regulates p21
Cdkn1a expression in Ba/F3 cells through the p53, PI3 kinase and PKA pathways
We previously showed that FLT3-ITD mutations increase Survivin expression in mouse Ba/F3 cells [30] and that Survivin enhances the proliferation of primary mouse HPCs through p21-dependent and p21-independent mechanisms [9] . Although p21 negatively regulates cell proliferation in a variety of cell systems [6] [7] [8] , these findings suggest that p21 may positively regulate FLT3-ITD signaling, similar to Survivin. We first investigated the association between p21 expression and cell proliferation in response to normal FLT3 and FLT3-ITD signaling. In IL-3-dependent Ba/F3 cells expressing wild-type human FLT3 (Ba/F3-FLT3), IL-3 withdrawal, which generally induces G 1 arrest, resulted in down-regulation of the p21
Cdkn1a protein and up-regulation of p27 Cdkn1b , a protein that normally inhibits the G 1 /S transition [33, 34] ( Fig   1A) . The stimulation of Ba/F3-FLT3 cells with FLT3 ligand (FL) concomitantly increased p21 protein levels and total cell number ( Fig 1B) . The ectopic expression of FLT3-ITD in Ba/F3 cells (FLT3-ITD + Ba/F3) significantly enhanced cell proliferation (Fig 1C) . These changes were coincident with the up-regulation of p21 and Survivin levels and a reduction in p27 Cdkn1b levels compared to cells expressing wild-type FLT3 (Fig 1D, upper panel) . Consistent with the upregulation of the p21 protein, p21 mRNA expression was significantly increased in FLT3-ITD + Ba/F3 cells compared to cells expressing wild-type FLT3 (Fig 1D, middle panel) . However, the selective FLT3-ITD inhibitor AC220 [24] significantly decreased p21 mRNA expression in FLT3-ITD + Ba/F3 cells (Fig 1D, lower panel) . Similarly, treatment of FLT3-ITD + cells with AG1296, which inhibits FLT3 kinase [35] , decreased p21 expression (not shown). Consistent with the FLT3-ITD + Ba/F3 cells, increased levels of the p21 protein were also observed in Sca-1 + , lineage-negative (KSL) cells as previously reported [30] (not shown), along with a significant up-regulation of the p21 mRNA in KSL cells (Fig 1F) . These data indicate that p21 expression is up-regulated by FLT3 signaling, and similar to Survivin, the increase is associated with enhanced or accelerated cell proliferation. Because p21 is one of the major transcriptional targets of p53 [1, 36] , we next investigated whether p53 is involved in the up-regulation of p21 induced by FLT3-ITD (Fig 2A) . Incubation of BaF3 cells with etoposide, which activates p53 [37] , increased p21 protein levels, indicating that p53 is functional in Ba/F3 cells. Etoposide-enhanced p21 expression was abrogated by the p53 inhibitor pifithrin-α [1, 38] FLT3-ITD attenuates the growth factor-independent proliferation and cell cycle progression of hematopoietic progenitor cells by up-regulating p21 Cdkn1a expression
The concurrent enhancement of cell proliferation and p21 up-regulation by FLT3-ITD suggested that p21 may positively regulate FLT3-ITD-potentiated cell proliferation, which was similar to our previous observations for the endogenous anti-apoptotic protein Survivin [30] . Therefore, we compared the functional roles of p21 and Survivin in the FLT3-ITD-induced growth factor-independent proliferation of HPCs. hematopoietic growth factors ( Fig 3A) . Conditional deletion of Survivin reduced the growth factor-independent proliferation of FLT3-ITD-transduced CFCs, as previously reported (Cre-ER Survivin fx/fx in Fig 3A) [30] . In contrast, deletion of the p21 gene increased the proliferation of CFCs transduced with FLT3-ITD ( Fig 3A) . An intermediate number of CFCs was generated by p21 +/-cells transduced with FLT3-ITD, indicating that the effect of p21 was gene dosage-dependent (Fig 3A, inset) . Similar to CFCs, the growth factor-independent proliferation of FLT3-ITD + KSL and c-kit + , lineage-negative (KL) cells was further enhanced by the deletion of p21 (P < 0.05, Fig 3B) . (Fig 3C) . Similarly, treatment with a p21-specific shRNA increased the growth factor-independent proliferation of FLT3-ITD + Ba/F3 cells compared to treatment with a control shRNA and was coincident with a marginal but significant increase in the number of cells in S+G 2 /M phase ( Fig 3D) . Moreover, p21 silencing increased the sensitivity of FLT3-ITD + Ba/F3 cells to the cell cycle-specific chemotherapeutic agent cytarabine (Ara-C) (Fig 3E) [39] . The 50% inhibitory concentrations (IC50s) of Ara-C were 0.6 and 0.27 μM in the control FLT3-ITD + Ba/F3 cells and those transduced with p21
shRNA, respectively. These data suggest that the FLT3-ITD-mediated up-regulation of p21 inhibits FLT3-ITD + cell proliferation and confers resistance to chemotherapy by delaying cell cycle progression.
Blocking p21 by FLT3-ITD inhibition facilitates the emergence of FLT3-ITD + cells that are refractory to the FLT3-ITD inhibitor AC220
The poor efficacy of FLT3-ITD inhibitors for FLT3-ITD + AML [22, 23] FLT3-ITD + Ba/F3 cells were cultured in the absence of cytokines with 2 or 5 nM AC220, a p21 expression levels (relative to actin) were quantitated by Western blot analysis and densitometry. The histogram beneath the blot indicates the percentages by which p21 expression was reduced by the inhibitors, which were averaged in 4 wells and determined by a comparison with the DMSO control (*: P < 0.05).
doi:10.1371/journal.pone.0158290.g002
Growth-Inhibitory Signaling in FLT3/ITD selective inhibitor of FLT3-ITD, for 24 hours, and FLT3 phosphorylation was inhibited ( Fig  4A) . Although the reduced FLT3 phosphorylation was not evident after 24 hours of incubation with 1 nM AC220, prolonged incubation with 1, 2 or 5 nM AC220 significantly inhibited the growth-factor independent proliferation of FLT3-ITD + Ba/F3 cells compared to the controls, suggesting that AC220 antagonizes the growth-stimulatory function of FLT3-ITD ( Fig  4B) . In contrast, the same treatment significantly decreased p21 mRNA expression in the FLT3-ITD + cells (Fig 4C) , implying that FLT3-ITD inhibition disrupts growth-inhibitory signaling pathways, and not just pathways that stimulate cell proliferation. When the FLT3-ITD + Ba/F3 cells were incubated with 1 or 2 nM AC220 for more than 8 days, cell proliferation began to increase despite the presence of AC220 (Fig 4B, left panel) . Similarly, the number of viable cells declined immediately after incubation with 5 nM AC220, but cells began to proliferate after 21 days in the presence of 5 nM AC220 (Fig 4B, right panel) , indicating the development of FLT3-ITD + cells that were refractory to AC220, as previously reported [30] .
Incubating the AC220-refractory cells with AC220 down-regulated p21 expression (Fig 4C) , suggesting that AC220 can also disrupt growth-inhibitory signaling in AC220-refractory FLT3-ITD + cells. However, p21 overexpression in the FLT3-ITD + Ba/F3 cells significantly delayed the emergence of AC220-resistant FLT3-ITD + cells (Fig 5A, left panel) and inhibited the proliferation of AC220-resistant FLT3-ITD + cells cultured in the presence of 2 nM AC220 for up to 60 days (Fig 5B) . The medium was replaced every 5 days, and fresh AC220 was added at a concentration of 2 nM; therefore, the emergence of resistant cells was not due to the loss of AC220 activity. The IC50 for the control FLT3-ITD + cells was 0.77 nM, whereas that in the cells expressing ectopic p21 was 0.65 nM on day 10 ( Fig 5A, right panel) . In contrast, p21 silencing with an shRNA significantly delayed the reduction in the number of viable FLT3-ITD + Ba/F3 cells induced by AC220 (Fig 6A, left panel) and accelerated the development and proliferation of FLT3-ITD + cells refractory to 2 nM AC220 up to 60 days (Fig 6B) .
The IC50 of AC220 for the FLT3-ITD + cells containing the control shRNA was 0.35 nM on day 10, whereas p21 silencing increased the IC50 to 0.7 nM (Fig 6A, right panel) . These findings suggest that the down-regulation of p21 resulting from FLT3-ITD inhibition facilitates proliferation and the development of FLT3-ITD + cells that are refractory to AC220. (Table 1 and S1 Table) . The 111 genes were functionally classified based on the biological process subclasses of the Gene Ontology database (Fig 7A) . The top 3 functional groups that were associated with p21 include the regulation of transcription (DNA-dependent), cell proliferation and phosphorylation. Among the 111 genes, 12 were deregulated in human AML stem cells (AML-LSC) ( Table 1 ) [40] . These 12 genes were further classified into 8 functional groups based on the Gene Ontology terms and the Swiss Protein database (Fig 7B) . The transcription factor Pbx1, which is associated with HSC and HPC function [28, 29] and is down-regulated in AML-LSC [40] , was up-regulated in FLT3-ITD + KSL cells upon p21 deletion. However, Pbx1 was not affected by p21 deletion in normal KSL cells (see below). Pbx1 itself was classified in 7 of the functional groups (Fig 7B) . Although the loss of p21 did not significantly affect Pbx1 expression in normal KSL cells (1.0 ± 0.3-fold change compared to p21 +/+ KSL cells, NS), the quantitative RT-PCR analysis confirmed that Pbx1 was up-regulated by 2.1 ± 0.5-fold in FLT3-ITD + p21 -/-KSL cells compared to FLT3-ITD + p21 +/+ KSL cells (P < 0.001, Fig 8A, left panel) . Because Pbx1 expression is transcriptionally regulated by the transcription factor Evi-1 [41] and FLT3-ITD and because p21 altered Pbx1 expression, we hypothesized that the changes in Pbx1 expression induced by FLT3-ITD and/or p21 are mediated by Evi-1. Therefore, we investigated the Evi-1 levels in the freshly isolated KSL cells and the FLT3-ITD-transformed KSL cells in the presence or absence of p21. However, p21 deletion had no effect on Evi-1 expression in normal or FLT3-ITD-transformed KSL cells (Fig 8A, right panel) . The Pbx1 mRNA levels in the p21 -/-KSL cells in G 0 and G 1 phases were equivalent to those in the p21 +/+ cells (1.0 ± 0.3-and 1.4 ± 0.3-fold changes, respectively), whereas Pbx1 expression in p21 -/-KSL cells in S phase was elevated by 6.1 ± 1.1-fold (P < 0.05, N = 3) compared to the p21 +/+ cells (Fig 8B) . Because Pbx1 expression was not modulated by p21 in the absence of FLT3-ITD, we next determined the effect of FLT3-ITD on Pbx1 expression. FLT3-ITD + Ba/F3 cells significantly down-regulated Pbx1 mRNA levels compared to FLT3-ITD -Ba/F3 cells (Fig 8C, left and middle panels) . Conversely, the FLT3-ITD inhibitor AC220 significantly up-regulated Pbx1 mRNA expression in the
The medium was replaced every 5 days and contained 5 nM fresh AC220. The cells were enumerated using the trypan blue exclusion assay. The y-axis represents the cell number on the log scale. The data shown represent one of the three experiments that were analyzed in triplicate with identical results (*: P < 0.05 compared to time 0, †: P < 0.05 compared to 1 or 2 nM AC220). (C) The relative expression of p21 in N51-FLT3-ITD-Ba/F3 cells that were sensitive or refractory to AC220 and incubated with 2 nM AC220 compared to those incubated with the DMSO control. The refractory cells, which were established by incubation with 2 nM AC220, were washed and cultured for 48 hours in fresh medium without AC220. The cells were subsequently incubated with 2 nM AC220 for 48 hours. Similarly, parental cells that were sensitive to AC220 were incubated with 2 nM AC220 for 48 hours. The p21 mRNA levels were quantitated before and after incubation with AC220 (*: P < 0.05, N = 3).
doi:10.1371/journal.pone.0158290.g004
Growth-Inhibitory Signaling in FLT3/ITD + AML HG-U133A and GSE30029, www.ncbi.nlm.nih.gov/geo/) [43] .
quantitated in the presence or absence of 2 nM AC220. The cells were plated at a density of 1x10 5 cells/ml and incubated with 2 nM AC220 or control DMSO for 10 days. The viable cells were enumerated using the trypan blue exclusion assay. The data shown represent one of three experiments that were analyzed in triplicate with identical results (*: P < 0.05 compared to the control shRNA). The expression levels of the p21 protein in both cell populations are shown in the inset (the same blot is shown in Fig 3D) . The right panel indicates the AC220 dosedependent inhibition of the control FLT3-ITD + cells containing empty vector and those with shRNA for p21. The cells were incubated with different concentrations of AC220 for 10 days, and the percent inhibition of viable cells was calculated compared to the control cells incubated with DMSO. (B) The panel indicates the numbers of viable FLT3-ITD + cells containing the empty vector or p21 shRNA that were cultured in the presence of 2 nM AC220 for 60 days. The cells were plated at a density of 1x10 5 cells/ml and were incubated with 2 nM AC220 or the DMSO control for 60 days. The medium was replaced every 5 days and contained 2 nM fresh AC220. P21 deletion in FLT3-ITD + KSL cells resulted in the modulation of the expression levels of 111 mRNAs that were either unaffected or differentially regulated in normal bone marrow KSL cells. Of these 111 genes, 12 were deregulated in human AML-LSC [40] . These genes were classified based on Gene Ontology terms and the Swiss Protein database (as shown in Fig 7B) . Pbx1 was classified into 7 of the functional groups. The fold changes in the expression levels of the genes listed in Fig 7B are shown in Table 1 . + KSL cells. These 111 genes were classified based on the Biological Process subclass of the Gene Ontology database using the DAVID program [44] . The network of representative biological processes was visualized using Cytoscape [45] . The size of the circle indicates the number of genes in a given category, and the thickness of the bar represents the redundancy between the groups. All of the gene 
Discussion
The present study shows that FLT3-ITD mutations produce proliferative and anti-growth signals (Fig 10A) . FLT3-ITD concomitantly up-regulated p21 expression and down-regulated Pbx1 expression. The loss of p21 enhanced the growth factor-independent proliferation and cell cycle progression of FLT3-ITD + cells and their sensitivity to Ara-C, suggesting that the enhanced expression of p21 attenuates cell cycle progression and confers chemoresistance to FLT3-ITD + cells. Furthermore, the p21 deficiency promoted the selective up-regulation of Pbx1 expression in FLT3-ITD + KSL cells, whereas silencing Pbx1 expression partially abrogated the enhanced proliferation of FLT3-ITD + HPCs induced by p21 deletion, indicating that the p21-mediated inhibition of the proliferation of FLT3-ITD + HPCs is mediated, at least in part, by Pbx1. Importantly, the p21 down-regulation resulting from FLT3-ITD inhibition by AC220 accelerated proliferation and development of FLT3-ITD + cells that were refractory to AC220, suggesting that treatments targeting FLT3-ITD can eradicate growth-inhibitory signals by inhibiting p21 expression, thereby potentially contributing to FLT3-ITD + AML progression (Fig 10B & 10C) .
lists and functional categories are shown in S1 Table. The array data have been deposited in the NCBI Gene Expression Omnibus (GSE75200). (B) The functional classifications of the 12 genes that were regulated by p21 in FLT3-ITD + KSL cells and deregulated in human AML-LSC [40] . The modulated genes were classified based on their biological processes and molecular functions, as defined by Gene Ontology terms and Swiss Protein keywords using the DAVID program [44] . Five of the 12 molecules were not classified. The 8 significantly enriched functional categories (P < 0.05) were connected and visualized using Cytoscape [45] . PBX1 was identified in 7 of 8 functional categories. The size of the circle indicates the number of genes in a given category, and the thickness of the bar represents the redundancy between the groups. The genes that were classified in each functional category are shown in the box. PBX1 is underlined. The fold changes in the expression levels of the listed genes are shown in Table 1 . effect, indicating that although FLT3-ITD enhances HPC proliferation, the concomitant increase in p21 expression attenuates their proliferation. Therefore, FLT3-ITD harbors both growth-inhibitory and growth-stimulatory activities (Fig 10A) . FLT3-ITD AML cells are characterized by their high proliferation rate and leukocytosis in patients [20, 21] . The presence of growth-inhibitory signaling downstream of FLT3-ITD appears to be contradictory to the increased proliferation potential of FLT3-ITD + AML cells. The majority of the signaling components that exist downstream of FLT3-ITD are known to contribute to cell proliferation [20, 21, 30] , suggesting that growth-stimulatory signaling dominates the p21-mediated inhibitory activity. The primitive KSL hematopoietic population exhibited the maximal increase in FLT3-ITD + cell proliferation in response to the loss of p21. In contrast, the effect of the loss of p21 was minimal in differentiated cells, suggesting that p21 attenuates the proliferation of early undifferentiated cells, which resemble AML stem cells. This result is in good agreement with the increased cell cycle progression in HSCs, without altering the marrow cellularity or peripheral blood cell counts in p21-deficient mice [8] . A previous report showed that the induction of cell cycle entry eliminated AML stem cells in Ara-C-treated mice [39] . The enhanced cytotoxic effect of Ara-C in FLT3-ITD + Ba/F3 cells induced by p21 silencing suggests that the up-regula- , AML1-ETO [4] and N-RasE12 [47] , all of which regulate the proliferation of myeloid leukemia cells, exhibit increased p21 expression. The loss of p21 facilitates AML1-ETO-induced leukemogenesis [4] and increases the proliferation of Bcr-Abl-transformed hematopoietic cells [46] , suggesting that these oncogenes also contain signaling components that negatively modulate the proliferation of leukemia cells. Moreover, the FLT3 ligand and stem cell factor provided by the bone marrow microenvironment [48] up-regulate p21 expression in Ba/F3-FLT3 cells and human AML cells [10, 11] , respectively. Taken together, these data indicate that p21 expression that is up-regulated by the oncogenes and/or hematopoietic growth factors derived from the marrow microenvironment may contribute to the chemoresistance of AML cells. Our data also indicate that the enhanced proliferation of FLT3-ITD + cells induced by the loss of p21 was accompanied by the up-regulation of Pbx1 expression. Pbx1 is a product of a proto-oncogene that was originally discovered in acute leukemia and critically regulates organogenesis and hematopoiesis [28] . Pbx1 regulates the self-renewal of hematopoietic stem cells by maintaining their quiescence, whereas it facilitates the expansion of HPCs by regulating the function of common myeloid progenitor cells [28, 29] . shRNA or control shRNA were transduced with a Pbx1-targeted shRNA or control shRNA. The cells were transfected with a p21 shRNA or a control shRNA and selected in the presence of 3 μg/ml puromycin for 2 weeks. The reduction in p21 expression was validated as shown in Fig 3D. The cells were then transfected with the control shRNA or two different shRNAs for Pbx1 (Pbx1 shRNA-1 and Pbx1 shRNA-2) and selected with 1 mg/ml G418 for 2 weeks. The reduction in Pbx1 mRNA expression was validated by Q-RT-PCR and shown in the inset (right). The cells were cultured in 1% FBS/RPMI without any growth factors for 10 days and enumerated using the trypan blue exclusion assay. The data shown represent one of three experiments that were performed in quadruplicate with identical results (*: P < 0.01 compared to the control shRNA paired with the Pbx1 shRNA). The top inset indicates the fold change in the cell number on day 10 compared to the FLT3-ITD + Ba/F3 cells containing two control shRNAs. The inset on the right demonstrates the fold change in the Pbx1 mRNA expression in the FLT3-ITD + Ba/F3 cells transduced with the Pbx1 shRNA compared to those transduced with the control shRNA paired with the Pbx1 shRNA (N = 3, P < 0.05). [20, 21, 30 ]. The present study shows that FLT3-ITD also generates a growth-inhibitory signal through p21, which is partially mediated by Pbx1. Because the signaling activity that stimulates cell proliferation or survival dominates the p21-mediated inhibitory signal, the FLT3-ITD + cells proliferate in the absence of a FLT3-ITD antagonist. (B) Antagonizing FLT3-ITD with AC220 can not only eradicate the growthstimulatory signals but also disrupt the growth-inhibitory signals by inhibiting p21 expression. FLT3-ITD + cells do not proliferate immediately after incubation with AC220. (C) Prolonged incubation of FLT3-ITD + cells with AC220 allowed the without FLT3 mutations. Although FLT3-ITD down-regulated Evi-1, a transcriptional regulator of Pbx1 [41] , p21 deletion had no effect on Evi-1 expression, irrespective of the FLT3-ITD status, suggesting that the p21-dependent modulation of Pbx1 expression is independent of Evi-1. Because p21 deletion in FLT3-ITD + HPCs marginally increased the percentage of cells in S+G 2 /M phase and the expression of Pbx1 was higher in S phase than in G1 phase, Pbx1 upregulation might be a consequence of cell cycle alterations induced by p21. A search of the chromosome 1 genomic contig of the Mus musculus strain C57BL/6J (MGSCv37 C57BL/6J: gi| 149245775) uncovered a potential non-coding sequence in the 5' region of the mouse Pbx1 gene. A transcription factor-binding analysis using up to 2.0 kb of the identified 5' non-coding sequence revealed candidate binding sequences for c-Myc, C/EBP-α and estrogen receptor-α, which are known to be directly regulated by p21 [15, 17, 18] . This result implies that c-Myc, C/ EBP-α or estrogen receptor-α may be involved in the p21-induced transcriptional regulation of Pbx1.
Conclusions
Our data demonstrate that FLT3-ITD attenuates FLT3-ITD + cell proliferation by modulating the p21/Pbx1 axis. Although the FLT3-ITD-mediated increase in p21 expression increases resistance to Ara-C by reducing cell cycle progression, disruption of p21 expression using an Supporting Information S1 
